Skip to search formSkip to main contentSkip to account menu

vibegron

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
To evaluate the efficacy of a novel and selective β3‐adrenoreceptor agonist vibegron on urgency urinary incontinence (UUI) in… 
Review
2020
Review
2020
Vibegron is a new kind of β3‐adrenergic receptor agonist. We performed a systematic review and pooled analysis to assess the… 
2020
2020
To examine vibegron effects on lower urinary tract dysfunction (LUTD) in mice with spinal cord injury (SCI). 
2019
2019
INTRODUCTION AND OBJECTIVES: Vibegron is a selective &bgr;3-adrenergic receptor agonist in development for overactive bladder… 
2018
2018
To evaluate the long‐term safety and efficacy of vibegron 50 mg and 100 mg, a novel β3‐adrenoreceptor agonist, in Japanese… 
2017
2017
Although the physiologic role of muscarinic receptors in bladder function and the therapeutic efficacy of muscarinic antagonists… 
Highly Cited
2016
Highly Cited
2016
The discovery of vibegron, a potent and selective human β3-AR agonist for the treatment of overactive bladder (OAB), is described…